Literature DB >> 26217077

Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective.

Tian Yang1, Wan-Yee Lau1, Han Zhang1, Bin Huang1, Jun-Hua Lu1, Meng-Chao Wu1.   

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related deaths worldwide. The Barcelona Clinic Liver Cancer (BCLC) classification has been endorsed as the optimal staging system and treatment algorithm for HCC by the European Association for the Study of Liver Disease and the American Association for the Study of Liver Disease. However, in real life, the majority of patients who are not considered ideal candidates based on the BCLC guideline still were performed hepatic resection nowadays, which means many hepatic surgeons all around the world do not follow the BCLC guidelines. The accuracy and application of the BCLC classification has constantly been challenged by many clinicians. From the surgeons' perspectives, we herein put forward some comments on the BCLC classification concerning subjectivity of the assessment criteria, comprehensiveness of the staging definition and accuracy of the therapeutic recommendations. We hope to further discuss with peers and colleagues with the aim to make the BCLC classification more applicable to clinical practice in the future.

Entities:  

Keywords:  Barcelona Clinic Liver Cancer Classification; Hepatectomy; Hepatocellular carcinoma; Prognosis; Staging system; Treatment

Mesh:

Year:  2015        PMID: 26217077      PMCID: PMC4507095          DOI: 10.3748/wjg.v21.i27.8256

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  46 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging.

Authors:  Tian Yang; Chuan Lin; Jian Zhai; Song Shi; Min Zhu; Nan Zhu; Jun-Hua Lu; Guang-Shun Yang; Meng-Chao Wu
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-10       Impact factor: 4.553

Review 3.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

4.  Reply to Letter: "Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on 'Surgical Misinterpretation' of the BCLC Staging System": Real Misinterpretation or Lack of Clarity Within the BCLC?

Authors:  Guido Torzilli; Jacques Belghiti; Norihiro Kokudo; Tadatoshi Takayama; Lorenzo Capussotti; Gennaro Nuzzo; Jean-Nicolas Vauthey; Michael A Choti; Eduardo De Santibanes; Matteo Donadon; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2015-07       Impact factor: 12.969

5.  Reply to Letter: "A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group": When the Study Setting "Ignores" the Patients.

Authors:  Guido Torzilli; Jacques Belghiti; Norihiro Kokudo; Tadatoshi Takayama; Lorenzo Capussotti; Gennaro Nuzzo; Jean-Nicolas Vauthey; Michael A Choti; Eduardo De Santibanes; Matteo Donadon; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2015-07       Impact factor: 12.969

6.  Is it a time to modify the BCLC guidelines in terms of the role of surgery?

Authors:  Norihiro Kokudo
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

7.  Management of spontaneous rupture of hepatocellular carcinoma: single-center experience.

Authors:  C L Liu; S T Fan; C M Lo; W K Tso; R T Poon; C M Lam; J Wong
Journal:  J Clin Oncol       Date:  2001-09-01       Impact factor: 44.544

Review 8.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 9.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.

Authors:  Mary Maluccio; Anne Covey
Journal:  CA Cancer J Clin       Date:  2012-10-15       Impact factor: 508.702

10.  Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort.

Authors:  Mark op den Winkel; Dorothea Nagel; Julia Sappl; Philip op den Winkel; Rolf Lamerz; Christoph J Zech; Gundula Straub; Thomas Nickel; Markus Rentsch; Petra Stieber; Burkhard Göke; Frank T Kolligs
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

View more
  6 in total

1.  Which factors affect the long-term survival of patients with hepatocellular carcinoma UICC stage IV?

Authors:  A Bauschke; A Altendorf-Hofmann; C Malessa; S Schüle; J Zanow; U Settmacher
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-15       Impact factor: 4.553

Review 2.  Controversies and evidence of hepatic resection for hepatocellular carcinoma.

Authors:  Jian-Hong Zhong; Guido Torzilli; Hao Xing; Chao Li; Jun Han; Lei Liang; Han Zhang; Shu-Yang Dai; Le-Qun Li; Feng Shen; Tian Yang
Journal:  BBA Clin       Date:  2016-10-11

Review 3.  Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy.

Authors:  Zhu-Jian Deng; Le Li; Yu-Xian Teng; Yu-Qi Zhang; Yu-Xin Zhang; Hao-Tian Liu; Jian-Li Huang; Zhen-Xiu Liu; Liang Ma; Jian-Hong Zhong
Journal:  J Clin Transl Hepatol       Date:  2021-08-10

4.  Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score.

Authors:  Yongjiang Li; Yangxun Pan; Ximeng Lin; Jingyu Hou; Zili Hu; Li Xu; Zhongguo Zhou; Yaojun Zhang; Minshan Chen; Dandan Hu
Journal:  Front Pharmacol       Date:  2022-02-08       Impact factor: 5.810

5.  Nomogram for preoperative estimation of long-term survival of patients who underwent curative resection with hepatocellular carcinoma beyond Barcelona clinic liver cancer stage A1.

Authors:  Dan-Yun Ruan; Ze-Xiao Lin; Tian-Tian Wang; Hui Zhao; Dong-Hao Wu; Jie Chen; Min Dong; Qu Lin; Xiang-Yuan Wu; Yang Li
Journal:  Oncotarget       Date:  2016-09-20

6.  Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems.

Authors:  R K Tannus; S R Almeida-Carvalho; C A Loureiro-Matos; A Miziara-Gonzalez; A A Salzedas-Netto; D Szejnfeld; G D'Ippolito; V Pereira-Lanzoni; I Souza-Silva
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.